文献速递细菌感染、耐药与抗菌药物医院感染防控

高耐药ICU脓毒症患者抗菌药物降阶梯治疗的多中心前瞻性队列研究

De-escalation of antimicrobial therapy in ICU settings with high prevalence of multidrug-resistant bacteria: a multicentre prospective observational cohort study in patients with sepsis or septic shock.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该多中心前瞻性观察性队列研究纳入262例脓毒症或脓毒性休克患者,评估在高耐药率ICU中抗菌药物降阶梯治疗的可行性与影响。结果显示仅22.9%的患者实际实施降阶梯,降阶梯与28天全因死亡率降低相关(13.3% vs 36.7%,OR 0.27,95%CI 0.11-0.66,P=0.006)。

要点

  • 高耐药ICU中仅22.9%患者可实施降阶梯,主要受多重耐药菌限制。
  • 降阶梯与28天死亡率降低独立相关(HR 0.31,95%CI 0.14-0.70)。
  • 降阶梯后SOFA评分出现后续 collateral 下降。

核心结论

  • 在高耐药率ICU中抗菌药物降阶梯可行性有限,但一旦可行并实施,与死亡率降低相关。

研究设计与样本

  • 多中心前瞻性观察性队列研究,纳入262例有明确感染灶的脓毒症患者。
  • 采用倾向性评分匹配(基于降阶梯启动当日SOFA评分)比较降阶梯组与未降阶梯组。

主要发现

  • 耐药病原体占62.9%,其中MDR 12.5%、广泛耐药49%、全耐药1.2%。
  • 97例(37%)因药敏结果判断降阶梯不可行。
  • 165例判断有降阶梯可能的患者中,仅60例(22.9%)实际实施降阶梯。
  • 匹配后120例患者中,降阶梯组28天全因死亡率13.3% vs 未降阶梯组36.7%(OR 0.27,95%CI 0.11-0.66,P=0.006)。
  • 降阶梯与ICU及住院死亡率降低相关,并与SOFA评分后续下降相关;Cox多因素回归显示降阶梯是28天生存的显著因素(HR 0.31,95%CI 0.14-0.70,P=0.005)。

临床怎么用

  • 在高耐药ICU中应积极评估降阶梯可行性,对药敏允许的患者实施降阶梯可能改善预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: De-escalation of empirical antimicrobial therapy, a key component of antibiotic stewardship, is considered difficult in ICUs with high rates of antimicrobial resistance. OBJECTIVES: To assess the feasibility and the impact of antimicrobial de-escalation in ICUs with high rates of antimicrobial resistance. METHODS: Multicentre, prospective, observational study in septic patients with documented infections. Patients in whom de-escalation was applied were compared with patients without de-escalation by the use of a propensity score matching by SOFA score on the day of de-escalation initiation. RESULTS: A total of 262 patients (mean age 62.2 ± 15.1 years) were included. Antibiotic-resistant pathogens comprised 62.9%, classified as MDR (12.5%), extensively drug-resistant (49%) and pandrug-resistant (1.2%). In 97 (37%) patients de-escalation was judged not feasible in view of the antibiotic susceptibility results. Of the remaining 165 patients, judged as patients with de-escalation possibility, de-escalation was applied in 60 (22.9%). These were matched to an equal number of patients without de-escalation. In this subset of 120 patients, de-escalation compared with no de-escalation was associated with lower all-cause 28 day mortality (13.3% versus 36.7%, OR 0.27, 95% CI 0.11-0.66, P = 0.006); ICU and hospital mortality were also lower. De-escalation was associated with a subsequent collateral decrease in the SOFA score. Cox multivariate regression analysis revealed de-escalation as a significant factor for 28 day survival (HR 0.31, 95% CI 0.14-0.70, P = 0.005). CONCLUSIONS: In ICUs with high levels of antimicrobial resistance, feasibility of antimicrobial de-escalation was limited because of the multi-resistant pathogens isolated. However, when de-escalation was feasible and applied, it was associated with lower mortality.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Routsi C, Gkoufa A, Arvaniti K, et al. De-escalation of antimicrobial therapy in ICU settings with high prevalence of multidrug-resistant bacteria: a multicentre prospective observational cohort study in patients with sepsis or septic shock. J Antimicrob Chemother. 2020. PMID: 32865203. doi:10.1093/jac/dkaa375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。